Breast SPORE Publications

Seattle Cancer Consortium Breast SPORE

Publications

2015 | 2014 | 2013 | 2012 | 2011

2015

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.
Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR.
Cancer Immunol Res. 2015 Feb;3(2):206-16. PMCID: PMC4324006

The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR.
Cancer Immunol Res. 2015 Feb;3(2):125-35. PMID: 25212991 (PMC in process)

Designing chimeric antigen receptors to effectively and safely target tumors.
Jensen MC, Riddell SR. Current Opinion in Immunology. 2015 Apr;33:9-15. PMCID: PMC4397136

Adoptive cellular therapy: a race to the finish line.
June CH, Riddell SR, Schumacher TN. Science Translational Medicine. 2015 Mar 25;7(280):280ps7. PMID: 25810311 (PMCID in process)

ToF-SIMS of tissues: "lessons learned" from mice and women.
Gamble LJ, Graham DJ, Bluestein B, Whitehead NP, Hockenbery D, Morrish F, Porter P.
Biointerphases. 2015 Mar 13;10(1):019008. PMCID: PMC4327923

Diffusion-weighted imaging: Effects of intravascular contrast agents on apparent diffusion coefficient measures of breast malignancies at 3 tesla.
Nguyen VT, Rahbar H, Olson ML, Liu CL, Lehman CD, Partridge SC.
J Magn Reson Imaging. 2015 Jan 22. doi: 10.1002/jmri.24844. [Epub ahead of print]. PMID:25611726

Comparison of Prone versus Supine 18F-FDG-PET of Locally Advanced Breast Cancer: Phantom and Preliminary Clinical Studies. Accepted Med Physics.
Williams JM, Rani S, Li X, Arlinghaus LR, Lee TC, MacDonald LR, Partridge SC, Kang H, Whisenant JG, Abramson RG, Peterson TE, Linden H, Kinahan PE, Yankeelov TE.
Med Physics. 2015 Jul;42(8):3801. PMCID: PMC4464063

Biopolymer implants enhance the efficacy of adoptive T-cell therapy.
Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT.
Nat Biotechnol. 2015 Jan;33(1):97-101. PMCID: PMC4289408

2014

Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
Zhao H, Faltermeier CM, Mendelsohn L, Porter PL, Clurman BE, Roberts JM.
Oncotarget. 2014 Dec 30;5(24):12704-14. PMCID: PMC4350358

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Jensen MC, Riddell SR.
Immunol Rev. 2014 Jan;257(1):127-44. PMCID: PMC3991306
Erratum in: Immunol Rev. 2014 Mar;258(1):259.

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.
Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ.
Cancer J. 2014 Mar-Apr;20(2):141-4. PMCID: PMC4149222

Serial transfer of single cell-derived immunocompetence reveals stemness of CD8+ central memory T cells.
Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, Drexler I, Höfer T, Riddell SR, Busch DH. Immunity. 2014 Jul 17;41(1):116-26. PMID: 25035956 (PMC in process)

α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.
Marcondes AM, Karoopongse E, Lesnikova M, Margineantu D, Welte T, Dinarello CA, Hockenbery D, Janciauskiene S, Deeg HJ.
Blood. 2014 Oct 30;124(18):2881-91. PMCID: PMC4215316

Breast DCE-MRI: influence of postcontrast timing on automated lesion kinetics assessments and discrimination of benign and malignant lesions.
Partridge SC, Stone KM, Strigel RM, DeMartini WB, Peacock S, Lehman CD.
Acad Radiol. 2014 Sep;21(9):1195-203. PMCID: PMC4166542

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins.
Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG.
Nat Methods. 2014 Feb;11(2):149-55. PMCID: PMC3922286

2013

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR.
Clin Cancer Res. 2013 Jun 15;19(12):3153-64. PMCID: PMC3804130

TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer.
Nauerth M, Weißbrich B, Knall R, Franz T, Dössinger G, Bet J, Paszkiewicz PJ, Pfeifer L, Bunse M, Uckert W, Holtappels R, Gillert-Marien D, Neuenhahn M, Krackhardt A, Reddehase MJ, Riddell SR, Busch DH.
Sci Transl Med. 2013 Jul 3;5(192):192ra87. PMCID: PMC3991308

Proliferation linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques.
Berger C, Berger M, Beard BC, Kiem H-P, Gooley TA, Riddell SR. PLoS One. 2013;8(2):e56268. PMCID: PMC3572023

Multicenter trials using 18F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs.
Kurland BF, Doot RK, Linden HM, Mankoff DA, Kinahan PE.
Clin Trials. 2013;10(6):886-95. PMCID: PMC4103752

In situ breast cancer and microchimerism.
Eun JK, Guthrie KA, Zirpoli G, Gadi VK.
Sci Rep. 2013;3:2192. PMCID: PMC3709160

Frailty Models for Familial Risk with Application to Breast Cancer.
Gorfine M, Hsu L, Parmigiani G.
J Am Stat Assoc. 2013 Dec 1;108(504):1205-1215. PMCID: PMC3963469

Bootstrap Inference for Network Construction with an Application to a Breast Cancer Microarray Study.
Li S, Hsu L, Peng J, Wang P.
Ann Appl Stat. 2013 Mar 1;7(1):391-417. PMCID: PMC3930359

A unified mixed-effects model for rare-variant association in sequencing studies.
Sun J, Zheng Y, Hsu L.
Genet Epidemiol. 2013 May;37(4):334-44. PMCID: PMC3740585

2012

Engineered T cells for anti-cancer therapy.
Turtle CJ, Hudecek M, Jensen MC, Riddell SR.
Curr Opin Immunol. 2012 Oct;24(5):633-9. PMCID: PMC3622551

Novel serial positive enrichment technology enables clinical multiparameter cell sorting.
Stemberger C, Dreher S, Tschulik C, Piossek C, Bet J, Yamamoto TN, Schiemann M, Neuenhahn M, Martin K, Schlapschy M, Skerra A, Schmidt T, Edinger M, Riddell SR, Germeroth L, Busch DH. PLoS One. 2012;7(4):e35798. PMCID: PMC3335788

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC. J Immunotherapy. 2012 Nov-Dec;35(9):689-701, 2012. PMCID: PMC3525345

Advances in molecular imaging for breast cancer detection and characterization.
Specht JM, Mankoff DA.
Breast Cancer Res. 2012 Mar 16;14(2):206. Review. PMCID: PMC3446362

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.
Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS.
Nat Med. 2012 Sep;18(9):1359-68. PMCID: PMC3677971
*Collaboration with FHCRC/UW Prostate SPORE

Accommodation of missing data in supportive and palliative care clinical trials.
Kurland BF, Johnson LL, Diehr PH.
Curr Opin Support Palliat Care. 2012 Dec;6(4):465-70. Review. PMID: 23042422

2011

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.
Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC.
Blood. 2011 Aug 4;118(5):1255-63. PMCID: PMC3152493

Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.
Currin E, Linden HM, Mankoff DA.
Curr Breast Cancer Rep. 2011 Dec;3(4):205-211.PMCID: PMC3480214

PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA.
Clin Cancer Res. 2011 Apr 15;17(8):2400-9. PMCID: PMC3086719

Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.
Turtle CJ, Riddell SR.
Curr Opin Immunol. 2011 Apr;23(2):299-305. PMCID: PMC3130496

Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA.
J Nucl Med. 2011 Oct;52(10):1541-9. PMCID: PMC3443079